These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1150 related articles for article (PubMed ID: 17084370)
41. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Jantunen E; Itälä M; Siitonen T; Koivunen E; Leppä S; Juvonen E; Kuittinen O; Lehtinen T; Koistinen P; Nyman H; Nousiainen T; Volin L; Remes K Eur J Haematol; 2006 Aug; 77(2):114-9. PubMed ID: 16856906 [TBL] [Abstract][Full Text] [Related]
42. [Primary treatment of advanced Hodgkin's disease]. Illés A; Udvardy M; Molnár Z Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586 [TBL] [Abstract][Full Text] [Related]
43. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
44. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410 [TBL] [Abstract][Full Text] [Related]
45. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802 [TBL] [Abstract][Full Text] [Related]
46. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060 [TBL] [Abstract][Full Text] [Related]
47. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837 [TBL] [Abstract][Full Text] [Related]
48. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index. Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649 [TBL] [Abstract][Full Text] [Related]
49. [Influence of age on treatment results in children and adolescents with Hodgkin's disease]. Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044 [TBL] [Abstract][Full Text] [Related]
50. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217 [TBL] [Abstract][Full Text] [Related]
51. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E; Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990 [TBL] [Abstract][Full Text] [Related]
52. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068 [TBL] [Abstract][Full Text] [Related]
53. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
54. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797 [TBL] [Abstract][Full Text] [Related]
55. Hodgkin's disease: controversies and challenges for the future. Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436 [No Abstract] [Full Text] [Related]
56. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
57. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563 [TBL] [Abstract][Full Text] [Related]
58. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results. Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855 [No Abstract] [Full Text] [Related]
59. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107 [TBL] [Abstract][Full Text] [Related]
60. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]